Application of glabridin liposomes in the preparation of drugs for the treatment of acute (chronic) cardiotoxicity induced by doxorubicin

A glabridin and cardiotoxicity technology, applied in the directions of liposome delivery, drug combination, pharmaceutical formulation, etc., can solve the problems of decreased myocardial contractility, increased myocardial fibrosis, congestive heart failure, etc. The effect of reducing myocardial toxicity and long degradation cycle

Inactive Publication Date: 2020-06-23
WUHAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In order to solve the problems in the prior art that when doxorubicin is used for anti-tumor treatment, it can induce apoptosis and necrosis of myocardial cells, increase myocardial fibrosis, reduce myocardial contractility, and eventually lead to ventricular remodeling and congestive heart failure. Provides the application of glabridin liposomes in the preparation of drugs for the treatment of acute (slow) cardiotoxicity induced by doxorubicin. The properties of glabridin liposomes are stable. Good biocompatibility, and it has been reported that glabridin can inhibit tumor growth

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of glabridin liposomes in the preparation of drugs for the treatment of acute (chronic) cardiotoxicity induced by doxorubicin
  • Application of glabridin liposomes in the preparation of drugs for the treatment of acute (chronic) cardiotoxicity induced by doxorubicin
  • Application of glabridin liposomes in the preparation of drugs for the treatment of acute (chronic) cardiotoxicity induced by doxorubicin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] [Example 1] Glabridin liposome preparation and characterization detection

[0025] (1) Glabridin liposome preparation

[0026] 1. Preparation method:

[0027] Weigh cholesterol, lecithin and glabridin and put them in a container, add chloroform-methanol mixed solution, the volume ratio of chloroform to methanol in the chloroform-methanol mixed solution=2:1, rotate at 50-60°C by rotary thin film evaporation method Make a film for 20-50min to make a uniform lipid dry film; the thickness of the lipid dry film is 0.1-0.2mm; dry the residual solvent with nitrogen, then add phosphate buffered saline solution with pH=7 to make the lipid film Fully swollen and hydrated, ultrasonicated for 5 minutes under the condition of ultrasonic power 400W, to obtain final product; in the ultrasonic, the frequency of ultrasonic for 5 seconds and stop for 5 seconds is carried out; the mass ratio of cholesterol to lecithin is cholesterol:lecithin=1: 5. The molar ratio of glabridin to lecithi...

Embodiment 2

[0071] [Example 2] Research on the effect of glabridin liposome on reducing the acute myocardial toxicity caused by doxorubicin

[0072] (1) Grouping and handling of animals

[0073] 6-8 weeks old C57BL / 6 male mice, 10 in each group, were divided into normal control group, model control group and glabridin liposome treatment group. (1) The normal control group was injected intraperitoneally with the same amount of normal saline every day for 7 consecutive days; (2) The model control group was injected with the same amount of normal saline intraperitoneally every day for 6 consecutive days, and DOX (doxorubicin) 20 mg / kg was injected intraperitoneally on the 7th day; ( 3) The glabridin liposome low-dose experimental group was injected intraperitoneally with 15 mg / kg glabridin liposome every day for 6 consecutive days, and on the seventh day, intraperitoneally injected DOX (doxorubicin) 20 mg / kg; (4) glabridin The liposome high-dose experimental group was injected intraperitone...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of glabridin lipidosome in preparing a drug for treating acute (chronic) cardiotoxicity induced by adriamycin. An appropriate amount of cholesterol, lecithin andglabridin are mixed, a chloroform-methanol mixed solution is added, a uniform lipid dry membrane is prepared by adopting a rotary film evaporation method, then a phosphoric acid buffer salt solutionwith a PH of 7 is added, the lipid membrane is sufficiently swelled and hydrated and is ultrasonically dispersed for 5 min under ultrasonic power of 400 W, and the glabridin lipdosome is obtained. Byvirtue of pretreatment of glabridin lipidosome for C57BL / 6 mice, then the mice are injected with adriamycin, and a myocardial enzyme level is reduced; and the weight loss of the mice is gradually reduced, which proves that the glabricin can alleviate the cardiotoxicity induced by the adriamycin and is safe and low in toxicity to normal cells of the human body.

Description

technical field [0001] The invention belongs to the field of Chinese herbal medicines, and in particular relates to a new application of glabridin liposome in reducing myocardial toxicity caused by doxorubicin. Background technique [0002] Heart failure is a complex clinical symptom group, which is a severe stage of various heart diseases. Its incidence rate is high, and its five-year survival rate is similar to that of malignant tumors. Half of the patients diagnosed with heart failure will die within 4 years, and the 1-year mortality rate of patients with severe heart failure is as high as 50%. Unlike other cardiovascular diseases, age-adjusted mortality from heart failure is still on the rise. Heart failure has increasingly become the most common and most harmful disease among cardiovascular diseases, and the causes of heart failure are very complex and diverse. Therefore, heart failure has become the focus and difficulty in the field of cardiovascular disease research....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/352A61K9/127A61K47/28A61P9/00A61P35/00
CPCA61K9/127A61K31/352A61K47/28
Inventor 周晓阳黄可晴杨静
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap